阿加曲班联合尿激酶治疗下肢深静脉血栓的临床研究  

Clinical Study of Argatroban Combined with Urokinasein Treatment of Lower Extremity DVT

作　　者：焦小平[1] JIAO Xiao-ping(Zhengzhou People s Hospital,Zhengzhou 450003,China)

机构地区：[1]郑州人民医院,郑州450003

出　　处：《中国合理用药探索》2020年第5期88-90,共3页Chinese Journal of Rational Drug Use

摘　　要：目的:探讨阿加曲班联合尿激酶治疗下肢深静脉血栓(LEDVT)的临床疗效及安全性。方法:将82例LEDVT患者采用随机数字表法分为对照组(n=41)和观察组(n=41)。两组采用尿激酶(60~80万IU/24 h持续泵入)实施经胫后静脉导管接触溶栓(CDT)治疗,观察组额外泵入阿加曲班(20 mg/次,bid),对照组皮下注射低分子肝素钙(5000 IU/次,bid),疗程为7天。比较两组的临床疗效及安全性。结果:观察组总体有效率为95.12%,高于对照组的80.49%(P<0.05)。治疗后两组患肢深静脉血流速度及通畅度评分均高于治疗前(P<0.05),且观察组高于对照组(P<0.05)。治疗后两组患者健/患肢周径差均小于治疗前(P<0.05),且观察组小于对照组(P<0.05)。观察组不良反应发生率为4.88%,低于对照组的19.51%(P<0.05)。结论:采用阿加曲班联合尿激酶实施CDT治疗LEDVT能提高临床疗效,改善相应症状,且安全性较好。Objective:To investigate the clinical effects and safety of argatroban combined with urokinase in treatment of lower extremity deep venous thrombosis(LEDVT).Methods:82 patients with LEDVT were randomly divided into control group(n=41)and observation group(n=41).Two groups were treated with urokinase(600000~800000 IU/24 h,continuous pumping)through posterior tibial venous catheter directed thrombolysis(CDT).The observation group was additionally pumped with agathuban(20 mg/time,bid).The control group received subcutaneous injection of low molecular heparin calcium(5000 IU/time,bid).The treatment course lasts for 7 days.The clinical effects and safety of the two groups were compared.Results:The overall effective rate of the observation group was 95.12%,significantly higher than 80.49%of the control group(P<0.05).After treatment,the blood flow velocity and patency score of the deep vein of the affected limb in two groups were higher than that before treatment(P<0.05),with more improvement observed in the observation group(P<0.05).After treatment,the peripheral diameter difference between healthy and affected limb in two groups was smaller than before treatment(P<0.05),with more reduction found in the observation group(P<0.05).The incidence of adverse reactions in the observation group was 4.88%,which was significantly lower than 19.51%in the control group(P<0.05).Conclusion:The CDT treatment of LEDVT with agartriban combined with urokinase shows significantly improved clinical effects,improves the corresponding symptoms and has a good safety.

关 键 词：阿加曲班 尿激酶 深静脉血栓 

分 类 号：R543.6[医药卫生—心血管疾病]